Prostate Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria. - Age >= 18 years - Willing to provide written informed consent - Histologically confirmed prostate adenocarcinoma (limited high-risk (>= cT3a, or GG >= 4, or PSA > 20ng/ml), locally progressive (any T, N1, M0) and oligometastatic (any T, any N, M1b <= 4 mid-shaft bone metastases)) - Received neoadjuvant therapy based on ADT±ARSI for 3-18 months - Radical prostatectomy (RP) has been performed after neoadjuvant therapy at Xiangya Hospital of Central South University
Exclusion criteria
Exclusion criteria: Exclusion criteria. - Prior radiation therapy, biological therapy - Prior immunotherapy/vaccine therapy for prostate cancer - Prior use of experimental drugs for prostate cancer - Combination therapy with other hormonal therapies or 5 alpha-reductase inhibitors - History or presence of autoimmune disease requiring systemic immunosuppression (including but not limited to: inflammatory bowel disease, systemic lupus erythematosus, vasculitis, rheumatoid arthritis, scleroderma, multiple sclerosis, hemolytic anemia, desiccation syndrome, and nodular disease) - History of malignancy within the past 3 years, except non-melanoma skin cancer and superficial bladder cancer - Uncontrolled major active infectious disease, cardiovascular disease, pulmonary disease, hematologic disease, or psychiatric disease that would make the patient a poor candidate for study - Known past or current history of HIV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic Complete Response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate specific antigen, PSA;clinical stage;MRD;times for neoadjuvant therapy; | — |
Countries
China
Contacts
Xiangya Hospital of Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan Province